Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Breast Density ≥ 50%
Intervention: Procedure: tomosynthesis
Sponsors: Alberta Health Services; Hologic, Inc.
Not yet recruiting - verified March 2010
Condition: Pulmonary Arterial Hypertension (Idiopathic, Familial or Anorexigen-associated)
Interventions: Drug: Dichloroacetate Sodium; Drug: Dichloroacetate Sodium; Drug: Dichloroacetate Sodium
Sponsors: University of Alberta; Imperial College London
Enrolling by invitation - verified March 2010
Condition: Cardiovascular Disease
Interventions: Drug: Active Clonidine; Drug: Placebo Clonidine; Drug: Active ASA; Drug: Placebo ASA
Sponsor: Hamilton Health Sciences
Not yet recruiting - verified March 2010
Condition: Acute Asthma
Interventions: Behavioral: Opinion Leader; Behavioral: Usual care
Sponsor: University of Alberta
Not yet recruiting - verified February 2010
Conditions: Migraine; Headache; Pediatric
Intervention: Drug: Normal saline
Sponsor: University of Alberta
Not yet recruiting - verified February 2010
Conditions: Multiple Sclerosis; Optic Neuritis; Minocycline
Intervention: Drug: Minocycline
Sponsors: University of Calgary; Neuroscience Canada
Recruiting - verified February 2010
Condition: Stress
Intervention: Behavioral: portable biofeedback tool and relaxation breathing technique
Sponsors: University of Calgary; Alberta Health Services; University of Calgary Department of Medicine and Faculty of Kinesiology
Completed - verified February 2010
Condition: Graft Versus Host Disease
Interventions: Drug: Rituximab; Drug: Prednisone
Sponsors: University Health Network, Toronto; Hoffmann-La Roche
Not yet recruiting - verified February 2010
Condition: Levels of Fatty Acids in the Blood Cells of Infants
Intervention:
Sponsors: Mead Johnson; University of Alberta
Recruiting - verified March 2010
Condition: Patients With Pacemaker With Conduction Problems
Intervention: Device: Pacing mode
Sponsors: Montreal Heart Institute; Sorin Group Canada
Active, not recruiting - verified November 2009
Condition: Severe Asthma
Intervention:
Sponsor: University of Alberta
Not yet recruiting - verified March 2010
Conditions: Myocardial Infarction; Stroke; Renal Failure
Interventions: Drug: atorvastatin 80 mg per os daily; Drug: placebo
Sponsor: University of Alberta
Recruiting - verified February 2010
Condition: Kidney Transplant
Interventions: Biological: Zostavax (Live attenuated herpes zoster vaccine); Biological: Placebo vaccine
Sponsor: University of Alberta
Recruiting - verified February 2010
Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Duke University; St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified February 2010
Condition: Heart Failure
Intervention: Device: Device programming
Sponsors: Montreal Heart Institute; St. Jude Medical; Canadian Institutes of Health Research (CIHR)
Active, not recruiting - verified May 2009
Condition: Heart Failure
Interventions: Device: CRT on; Device: CRT off
Sponsors: Montreal Heart Institute; St. Jude Medical; Canadian Institutes of Health Research (CIHR)
Recruiting - verified May 2009
Condition: Malignant Melanoma
Interventions: Drug: ABI-007; Drug: Dacarbazine
Sponsors: Abraxis BioScience Inc.; University of Arizona
Recruiting - verified August 2009
Condition: Cardiovascular Disease
Interventions: Drug: active clonidine; Drug: active ASA; Drug: Clonidine Placebo; Drug: ASA Placebo
Sponsors: McMaster University; The Physicians' Services Incorporated Foundation; Canadian Network and Centre for Trials Internationally
Completed - verified March 2010
Conditions: HIV Infection; Herpesvirus 2, Human; HIV Infections
Interventions: Drug: valacyclovir; Drug: Placebo
Sponsor: University Health Network, Toronto
Recruiting - verified March 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified October 2009
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2189265; Drug: Sitagliptin 100mg, 24 months; Drug: Placebo solution; Drug: Placebo tablet, 6 months; Drug: Placebo tablet, 24 months; Drug: Sitagliptin 100 mg, 18 months
Sponsors: Eli Lilly and Company; United BioSource Corporation; Tessella Inc.; Berry Consultants
Recruiting - verified March 2010
Conditions: Neoplasm; Lymphoma
Intervention: Drug: ridaforolimus
Sponsors: Ariad Pharmaceuticals; H. Lee Moffitt Cancer Center and Research Institute; Pediatric Cancer Foundation; University of Colorado, Denver; All Children's Hospital; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel; Drug: Prasugrel; Drug: Commercially-available Aspirin
Sponsors: Eli Lilly and Company; Daiichi Sankyo Co., Ltd.; Duke University
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: vandetanib; Drug: Placebo
Sponsors: AstraZeneca; Canadian Urology Research Consortium
Terminated - verified February 2010
Conditions: Ovarian Carcinoma; Breast Cancer
Intervention: Drug: AZD2281
Sponsors: AstraZeneca; British Columbia Cancer Agency
Active, not recruiting - verified March 2010
Condition: Pneumothorax
Interventions: Procedure: chest drainage; Other: close clinical observation
Sponsors: University of Calgary; Centre Hospitalier Affilie, Universitaire de Quebec; Sunnybrook Health Sciences Centre; Canadian Intensive Care Foundation
Recruiting - verified March 2010
Condition: Advanced Glenohumeral Arthritis
Intervention: Device: Humeral surface replacement hemiarthroplasty (CAP)
Sponsors: University of Calgary; DePuy International; Johnson & Johnson
Recruiting - verified March 2010
Condition: Cystic Fibrosis
Interventions: Drug: azithromycin 250 mg tablets; Drug: placebo tablets
Sponsors: CF Therapeutics Development Network Coordinating Center; Cystic Fibrosis Foundation
Completed - verified February 2010
Condition: Supraventricular Tachycardia in Infants
Intervention: Drug: digoxin and propranolol
Sponsors: University of British Columbia; The Hospital for Sick Children; University of Utah
Recruiting - verified February 2010
Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified March 2010
Condition: Breast Neoplasms
Interventions: Drug: CP-751,871 + exemestane; Drug: exemestane
Sponsors: Pfizer; Massachusetts General Hospital
Recruiting - verified March 2010
Condition: Alcoholism
Intervention: Procedure: Internet personalized alcohol feedback (PAF)
Sponsors: Centre for Addiction and Mental Health; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Completed - verified March 2010
Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; The Cleveland Clinic
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Procedure: 7800 cGy/39 fractions in 8 weeks; Procedure: 6000 cGy/20 fractions in 4 weeks
Sponsors: Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Radiation: 3D-CRT APBI; Radiation: WBI
Sponsors: Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Canadian Breast Cancer Research Alliance
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Biological: pegfilgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate
Sponsors: European Organization for Research and Treatment of Cancer; Lymphoma Trials Office; Groupe d'Etudes de Lymphomes de L'Adulte; Grup per l'Estudi dels Limfomes de Catalunya i Balears; NCIC Clinical Trials Group; Australasian Leukaemia and Lymphoma Group (ALLG); Nordic Lymphoma Group
Active, not recruiting - verified June 2009
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); Radiation Therapy Oncology Group; Southwest Oncology Group; Trans-Tasman Radiation Oncology Group (TROG); North Central Cancer Treatment Group
Active, not recruiting - verified March 2010
Conditions: Hypertension, Pulmonary; Respiratory Insufficiency; Infant, Newborn, Diseases; Meconium Aspiration; Persistent Fetal Circulation Syndrome; Pneumonia, Aspiration; Respiratory Distress Syndrome
Interventions: Drug: Inhaled nitric oxide; Drug: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Medical Research Council of Canada
Terminated - verified November 2009
Condition: Lymphoma
Intervention: Biological: rituximab
Sponsors: University of California, Los Angeles; National Cancer Institute (NCI); Genentech
Completed - verified February 2010
All Categories ... University Studies » ... Canada » ... Alberta 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
